title: Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting.
abstract: The relationship between nevirapine plasma concentrations and the durability of both viral suppression (VS) and selection of nevirapine primary resistance mutations (PRMs) was evaluated. A nevirapine trough concentration (Ctrough) of >4,300 ng/ml was found to predict longer VS. Patients with nevirapine Ctrough s ranging from 3,100 to 4,300 ng/ml had higher probabilities of developing PRMs than those with nevirapine Ctrough s below and above this concentration interval.
authors.affiliation: Department of Infectious Diseases, University of Turin, Italy.
authors.forename: D
authors.initials: D
authors.lastname: González de Requena
authors.forename: S
authors.initials: S
authors.lastname: Bonora
authors.forename: S
authors.initials: S
authors.lastname: Garazzino
authors.forename: M
authors.initials: M
authors.lastname: Sciandra
authors.forename: A
authors.initials: A
authors.lastname: D'Avolio
authors.forename: R
authors.initials: R
authors.lastname: Raiteri
authors.forename: R
authors.initials: R
authors.lastname: Marrone
authors.forename: M
authors.initials: M
authors.lastname: Boffito
authors.forename: F G
authors.initials: FG
authors.lastname: De Rosa
authors.forename: A
authors.initials: A
authors.lastname: Sinicco
authors.forename: G
authors.initials: G
authors.lastname: Di Perri
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D024882:Drug Resistance, Viral; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D008297:Male; D009154:Mutation; D019829:Nevirapine / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D012372:ROC Curve; D012189:Retrospective Studies
chemical_list: D019380:Anti-HIV Agents; D019829:Nevirapine